Please assess the completion status of the following clinical trial:

Trial Title: Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult males 18 years or older~* Severe hemophilia A (F.VIII \< 0.01 U/ml)~* At least 150 exposure days to F.VIII products~* No detectable inhibitor~* No history of allergic reaction~* Platelets at least 150,000/ul~* If HIV(+), CD4 at least 200/ul, HIV-VL \<48 copies/ml,and cART compliant~* If HCV(+), no splenomegaly,varices,GI bleed,ascites,edema,encephalopathy~* Willingness to comply with cross-over design, randomization schema~* Willingness to keep a personal diary of bleeding frequency and factor use~* Willingness to make every 3 month visits, coagulation testing at wks 2, 28~Exclusion Criteria:~* Acquired hemophilia~* Any bleeding disorder other than hemophilia A~* Presence of an inhibitor to factor VIII~* Historic platelet count \< 100,000~* Use of experimental drugs~* Surgery anticipate in the next 52 weeks~* Symptomatic HCV(splenomegaly,varices,GI bleed,ascites,edema,encephalopathy)~* Symptomatic HIV(CD4\<200/ul or HIV VL 48 or more copy/ml,cART noncompliant)~* Life expectancy less than 5 years~* Investigational drug or study within 4 weeks prior to study~* Inability to comply with study requirements

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): The intervention for Arm A is 40 IU/kg recombinant factor VIII (rFVIII) by once-weekly intravenous injection for 26 weeks.~Cross-over will occur at 26 weeks after a 72 hour washout period, after which 40 IU/kg recombinant factor VIII (rFVIII) will be given thrice-weekly by intravenous injection until week 52, with up to two rescue doses per week for bleeds.
- Arm B (Type: EXPERIMENTAL): The intervention for Arm B is 40 IU/kg recombinant factor VIII (rFVIII) by thrice-weekly intravenous injection for 26 weeks.~Cross-over will occur at 26 weeks after a 72 hour washout period, after which 40 IU/kg recombinant factor VIII (rFVIII) will be given once-weekly by intravenous injection until week 52, with up to two rescue doses per week for bleeds

Based on this trial design, predict the completion outcome and termination type (if applicable).